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Abstract
Background: The ideal evidence to answer a question about the effectiveness of treatment is a systematic review.
However, for many clinical questions a systematic review will not be available, or may not be up to date. One
option could be to use the evidence from an individual trial to answer the question?
Methods: We assessed how often (a) the estimated effect and (b) the p-value in the most precise single trial in a
meta-analysis agreed with the whole meta-analysis. For a random sample of 200 completed Cochrane Reviews
(January, 2005) we identified a primary outcome and extracted: the number of trials, the statistical weight of the
most precise trial, the estimate and confidence interval for both the highest weighted trial and the meta-analysis
overall. We calculated the p-value for the most precise trial and meta-analysis.
Results: Of 200 reviews, only 132 provided a meta-analysis of 2 or more trials, with a further 35 effect estimates
based on single trials. The average number of trials was 7.3, with the most precise trial contributing, on average,
51% of the statistical weight to the summary estimate from the whole meta-analysis. The estimates of effect from
the most precise trial and the overall meta-analyses were highly correlated (rank correlation of 0.90).
There was an 81% agreement in statistical conclusions. Results from the most precise trial were statistically signifi-
cant in 60 of the 167 evaluable reviews, with 55 of the corresponding systematic reviews also being statistically
significant. The five discrepant results were not strikingly different with respect to their estimates of effect, but
showed considerable statistical heterogeneity between trials in these meta-analyses. However, among the 101
cases in which the most precise trial was not statistically significant, the corresponding meta-analyses yielded 31
statistically significant results.
Conclusions: Single most precise trials provided similar estimates of effects to those of the meta-analyses to which
they contributed, and statistically significant results are generally in agreement. However, “negative” results were
less reliable, as may be expected from single underpowered trials. For systematic reviewers we suggest that: (1) key
trial(s) in a review deserve greater attention (2) systematic reviewers should check agreement of the most precise
trial and the meta analysis. For clinicians using trials we suggest that when a meta-analysis is not available, a focus
on the most precise trial is reasonable provided it is adequately powered.
Background
Clinical decisions are ideally informed by a systematic
review that finds, selects, and synthesizes the best pri-
mary studies that answer a single question [1]. Though
the Cochrane Collaboration has completed over 3,000
systematic reviews in the past decade, this is around
15% of the number required [2], and updates are proble-
matic. Those teaching “bedside” evidence-based medi-
cine [3,4] suggest clinicians identify and appraise the
single “largest” trial and use this as the basis of conclu-
sions. Ideally new trials would report their results in the
context of all previous relevant research, but this is
rarely done [5]. This leaves practitioners wishing to base
decisions on evidence with the dilemma of using a sin-
gle trial or disregarding evidence.
Doing a systematic review is not practical in daily clin-
ical practice or for the all the questions that arise when
writing a guideline. Hence if no review is currently avail-
able then clinicians or guideline writers must decide
whether to rely on the best single study or invest the
considerable effort involved in doing a systematic
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meta-analyses [6] showed that the average hours for a
review were 1,139 (median 1110) – or about 30 person-
weeks of full-time work –with a range from 216 to 2518
hours. As a consequence, most trials have never been
included in a systematic review. Clinicians therefore
often attempt to do a rapid “best trial” review process
which will take a few hours or less - over a hundred-
fold less effort - but with clear risks of drawing inap-
propriate conclusions based on a limited search and sin-
gle trials. The two processes are contrasted in Figure 1.
The major reasons for undertaking meta-analyses are
(i) the additional statistical power provided by pooling
several studies, and (ii) the ability to explore the robust-
ness of different versions of an intervention across dif-
fering populations. However there are also downsides:
pooling several small studies increases the risk of detect-
ing publication bias rather than a real effect, and also a
focus on pooling may distract from the quality of and
question asked by individual studies.
Clearly a single trial can sometimes be sufficient to
guide clinical decision making: for hormone replacement
therapy the Women’s Health Initiative (WHI) trial pro-
vides a large percentage of the available trial evidence.
While systematic reviews of hormone replacement ther-
apy may be valuable for an examination of consistency
and additional outcomes, the WHI alone is a sufficient
basis for many clinical decisions. However, most clinical
questions will not have such a clear dominant trial. As
illustrated in Figure 1, the evidence process then con-
sists of two stages: (i) find a recent systematic review
(hopefully), but if there isn’t one then find the “best”
trial - the most precise - and (ii) appraise and (if appro-
priate, and no important flaws) apply the trial results.
The first step is not straightforward, but is only worth-
w h i l ei ft h es e c o n ds t e pw i l lu s u a l l yp r o v i d eas u f f i -
ciently good answer compared with an up-to-date
systematic review. Therefore, as an initial exploration of
this process, we decided to examine how well and how
frequently the single “best” trial might answer the clini-
cal question.
Previous studies have looked at the special case of
agreement between “mega-trials” and meta-analyses [7],
but no studies appear to have examined a more repre-
sentative sample of reviews. We aimed to evaluate in a
random selection of systematic reviews how often, and
under what circumstances, using the trials with the
greatest statistical weight arrives at similar conclusions
to the full meta-analysis.
Methods
For a sample of reviews we selected the trial that con-
tributed the most weight to the meta analysis as the
most informative trial and aimed to compare its results
to that of the meta analyses of the main outcome mea-
sure in the systematic review. The systematic reviews
Figure 1 Two options for addressing a clinical question based on research literature: (a) a full systematic review and (b) a rapid “best
trial” review. This paper compares the elements in the shaded boxes.
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issue 1, 2005 of the Cochrane Database of Systematic
Reviews. For each systematic review sampled two of us
(PB, SS) independently extracted data on the title, date of
the last search, the number of trials included, and
whether a meta-analysis was done on the trials. If a
meta-analysis was undertaken, then we aimed to use the
main outcome for each review. We identified the main
outcome from the question in the Methods section and
tried to find a match in the results. If the data was not
pooled for the main outcome, then the closest match
among the meta-analyzed results was chosen. We
extracted data on the type of measure of effect, the point
estimate and its 95% confidence interval, the p-value, and
the I
2 for heterogeneity. For the main outcome we identi-
fied the “largest” ( m o s tp r e c i s e )s i n g l et r i a l ,w h i c hw e
defined for this paper as the trial contributing the great-
est weight to the meta-analysis. For this trial we extracted
data on the weight and size of the trial, the point esti-
mate and 95% confidence interval, and p-value. We also
recorded the direction of outcome of all of the trials (in
favor of, neutral, or against the main treatment). We
relied on the authors of the review to choose whether a
fixed or a random effects model was appropriate, and did
not redo their meta-analytic results.
Analyses
We compared the estimates of effect from the trial with
the most weight with that from the whole meta-analysis.
To use consistent methods within and between reviews,
w ec a l c u l a t e dt h epv a l u ef o rt h et r i a lb yaz - t e s t( l o g -
transformed for dichotomous data) rather than use the
p-values calculated by various means in the individual
trials.. We compared the p-value of the trial with the
p-value obtained from the meta-analysis. To dichotomize
the p-value results, we classed trials and meta-analyses as
statistically significant if the p-value was less than 0.05.
Results
Of the 200 randomly selected Cochrane reviews, 132
(66%) had a meta-analysis which included 2 or more
trials. Of the other 68 reviews, 12 had no trials, 35
included only a single trial, and 21 had no meta-analysis
as the trials could not be pooled, Of those trials with a
meta-analysis, the average number of trials included in
the meta-analysis of the main outcome was 7.3 trials,
w h i c hi ss i m i l a rt oap r e v i o u sa n a l y s i so fa l lC o c h r a n e
reviews in 2001 [8]. The median weight of the most pre-
cise trial within the meta-analysis was 51%, that is, the
majority of the weight of the meta-analysis. The major-
ity had little heterogeneity with a median I
2 of 1.2%.
Further details are given in Table 1.
For 184 relevant reviews (for 12 reviews there were no
trials, and in 4 without meta-analysis we could not tell
which was the trial with the greatest weight) the trial
with the most weight was present in MEDLINE in 89%
(162 of 184) of the reviews. 20 were only found in other
databases, and 1 was unpublished.
The estimates of effect for the most precise trial and
meta-analysis were generally similar. The Pearson rank
correlation was 0.90. Figure 2 is a scatter plot of the
results (excluding those meta-analyses that had only a
single trial, which would all lie along the diagonal), sub-
g r o u p e db yw h e t h e rt h ei n d e xt r i a lw a sm o r eo rl e s s
than 50% of the weight in the meta-analysis, irrespective
of the absolute size of the trial. The upper figures are
for ratio measures (relative risk, odds ratio, or hazard
ratio); the lower figures are for weighted mean differ-
ences. The two off diagonal quadrants show some dis-
agreements in direction of effect, but mostly when both
estimates are close to an RR of 1.
Of the 167 with either a summary result, a meta-ana-
lysis, or a single trial 86 (51%) showed statistically signif-
icant results. Figure 3 shows the comparison of p-values
from the most precise trial and the meta-analysis. The
dotted lines divide the plot into a 2 × 2 table with the
two boxes along the diagonal representing areas of
“agreement” and the two off diagonal areas (between the
dotted lines and axes) representing the “disagreements”.
These results are summarized in Table 2, which shows
that the statistical conclusions agreed in 135 pairs (81%).
Most disagreements were where the systematic review
found a statistically significant result when the most
precise single trial did not. However, in 5 cases, the
most precise single trial was significant when the meta-
analysis was not on the same outcome measure. These
disagreements were surprising, and hence we sought to
understand the possible reasons in more detail.
Table 1 Components of the 132 systematic reviews that included a meta-analysis
Mean (SD) Median Range Comments
Trials in the meta analysis 7.3 (11.6) 4.0 2 to 184 Does not include the 35 reviews with a single trial
Weight of the most precise trial 50% (22.0)+- 51% 3.3 to 96.4 Weight is based on the inverse variance calculated in RevMan
Sample size in most precise trial 1148 (7392) 183 14 to 82,892
P value for meta analysis 0.21 (0.29) 0.03 0.0 to 0.99
Degree of Heterogeneity - I
2 26.6% (30%) 1.2% 0% to 90% Does not include the 35 reviews with a single trial
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Page 3 of 7Why do they disagree? I - SR non-significant but
big trial significant
The 5 disagreements are detailed in Table 3. In one
case (row 1 of Table 3) the disagreement was minor
(p = 0.06 versus 0.04), but in the other 4 cases the dis-
agreement was more substantial. However, in no case
was the direction of effect reversed. Of note is the high
degree of heterogeneity found in all 5 cases, with the
least being an I
2 of 54%. In two cases there was also
important clinical heterogeneity, so that the intervention
in the most precise trial appeared to be importantly dif-
ferent to the intervention in other trials. For example, in
the review of several trials of DOTS (Directly Observed
Therapy - having a health care worked observe the
patient take their daily medication) for tuberculosis, the
location of the intervention differed from patients need-
ing to go for daily visits to a health centre to home visits
by a health care worker or family member, but there are
also methodological concerns with the trial that might
explain the difference. The latter is clearly easier for
patients to adhere to, and showed a positive effect
whereas the pooled results did not. The 2 trials in infan-
tile spasm used very difference dosages, and again meta-
analytic pooling is questionable.
Figure 2 Estimates of effect for the index (highest weighted) trials compared to the meta-analysis (larger circles have higher weight
within the review): A. Relative Risks (RR) where the index trial is more than 50% of the weight (A1) and less than 50% (A2); B. Weighted Mean
Differences where the index trial is more than 50% of the weight (B1) and less than 50% (B2) - note: for the 4 trials and meta-analyses with
WMDs more than 10 (or -10) we rescaled to fit.
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non-significant
In 31 of 86 statistically significant meta-analyses the
most precise trial was not statistically significant. This
“disagreement” is less surprising, as many of these most
precise trials were still clearly underpowered for the key
outcome measure. Of note is that the trial confidence
interval did include the systematic review’so v e r a l l
estimate in 25 of the 31 cases, and the confidence inter-
vals overlapped in all but 1 case.
Discussion
Among the reviews we examined the level of statistical
significance between the majority of meta analyses and
the trials with the most weight was in agreement. In
particular if the trial with the most weight is statistically
Figure 3 Scatter plot of p-values from the 132 meta-analyses (x-axis) compared to p-values from the most precise trial (y-axis). Values
in the lower left and upper right quadrants are in agreement; those in (i) the upper left and (ii) lower right are in disagreement.
Table 2 Agreement on statistical significance between the overall results of the systematic review and the most
precise single trial
1
Meta-analysis or single trial
Large Trial P < 0.05 P > 0.05
P < 0.05 55 (including 14 single trial reviews) 5
p > 0.05 31 70 (including 15 single trial reviews)
1 Six single trial reviews are excluded due to insufficient data
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Page 5 of 7significant, then the meta-analysis is usually also statisti-
cally significant. However, if the trial with the most
weight is non-significant, the meta-analysis was statisti-
cally significant in about 1/3 of the reviews (31/101,
31%), suggesting that even those trials with the most
weight were often underpowered.
A limitation of our analysis is that we have treated
meta-analysis as if it were a “gold standard”. However
there are a number of studies suggesting they are not.
For example, in an analysis of multiple systematic
reviews on 17 topics in complementary medicine [9] the
authors stated “we were surprised by the number and
scale of the discrepancies.” Among reviews comparing
the results of large-trials (trials with more than
1,000 patients) with the results of meta-analyses agree-
ment ranging from kappas of 0.22 to 0.72 was reported,
depending on the methods used. One of the better ana-
lysis [7] observed that large trials disagreed with meta-
analyses 10% to 23% of the time. These analyses treated
the large-trial as the gold standard, but again large trials
of the same clinical question do not always agree. A
study of 422 pairs of mega-trials found only modest
agreement in the results with a weighted kappa of 0.40,
though only 2% of trial pairs showed a statistically sig-
nificant differences in opposite directions [10].
As indicated in the introduction, we have not
addressed how to find the “best” trial, but only the next
step of what we could conclude if we did. However
identifying the best or most precise trial may not be
simple, and further research is warranted to examine
different methods to identify key trials among all the
t r i a l s .T h e s ea r em o r el i k e l yt ob ei nM E D L I N E ,b ei n
major journals, and be multi-center, but we don’tk n o w
the accuracy of different filtering heuristics. Filters or
tagging for key trials would be valuable when no sys-
tematic review is available. Since the power of studies is
not always proportional to the sample, the “most pre-
cise” trial may be difficult to identify even if it is among
the search results. The closest equivalent would be to
base the choice on the width of confidence intervals, but
these are often not reported in the abstracts. A potential
alternative would be the number of events [11], but
again this is often not reported in abstracts. Clearly if
rapid searching is to be viable, more research is needed
into these options. Finally as suggested in Figure 1, even
if the most precise trial is identified, it still needs to be
critically appraised, and, if unacceptably flawed, the sec-
ond most precise trial examined, etc.
For clinicians and guideline authors trying to use sys-
tematic reviews and trials, we cautiously suggest that
when a meta-analysis is not available, then a focus on
the most precise trial is reasonable provided it is ade-
quately powered (that is the confidence intervals exclude
values that would change the clinical decision) and ade-
quately conducted. If there is no existing systematic
review, those needing an answer to a clinical question,
but without the time or resources to undertake a meta-
analysis, might search for the most precise well-con-
ducted trial and carefully check whether the study was
sufficiently large. However, particular caution is needed
about making negative conclusions based on small trials.
Though not our primary focus, the results also have
some implications for systematic reviewers. The key trial
(s) included in a review may deserve greater attention. If
a trial provides a substantial portion of the weight in a
review, it deserves careful analysis and comparison with
the other trials. This is in part an error check: the index
trial will usually be close the overall result. Such a check
may have prevented the error that occurred in one
Cochrane review where the direction of effect of most
trials had been coded in the wrong direction [12]. The
opposite conclusion from the index trial could have
alerted the reviewers to a possible problem.
It may be prudent for systematic reviewers to check
agreement of the most precise trial and the meta analy-
sis. If the results of the large trial and the meta analysis
Table 3 Reviews where the most precise trial was statistically significant but the meta-analysis was not, with the
p-value and effect estimates* of both
Title of review Outcome measure Number
of trials
P value of meta analysis
vs most precise trial (trial
weight)
Estimate of effect for
meta analysis vs most
precise trial
I
2
Prophylactic antibiotics for preventing early central
venous catheter Gram positive infections in
oncology patients
Catheter related
sepsis
4 0.06 vs <0.04 (51%) OR 0.55 vs 0.35 54%
Azithromycin for acute lower respiratory tract
infections
Clinical failure 14 0.9 vs < 0.001 (14%) RR 0.96 vs 0.52 58%
Directly observed therapy for treating tuberculosis Cure 4 0.1 vs < 0.006 (60%) 1.06 vs 1.13 64%
Laparoscopic colposuspension for urinary
incontinence in women
Number
subjectively cured
within 18 months
3 0.9 vs < 0.025 (56%) RR 1.0 vs 1.05 73%
Treatment of infantile spasms Cessation of spasms 2 0.1 vs < 0.02 (65%) OR 2.57 vs 1.35 69%
* OR is the Odds Ratio; RR is the Relative Risk; I
2 is the heterogeneity proportion.
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Page 6 of 7are inconsistent (as in Table 3) then reviewers should be
careful about pooling for two reasons. First, the smaller
trials may be of lower methodological quality: an analy-
sis of 190 trials within 14 meta-analyses, smaller trial
were 3 times more likely to be of low quality [13].
Conclusions
In general, a systematic review is preferred particularly
when all trials are underpowered. Even when a domi-
nant well-powered study or trials exist other trials can
still provide additional useful information, e.g, sub-
groups, robustness of findings across groups. Hence sys-
tematic reviews are generally likely to be among the
most cost-effective types of research [14]. However,
given the current limited resources to conduct systema-
tic reviews, the full process might be reserved for crucial
issues or prior to large trials, and, whether or not a
meta-analysis is done, greater attention should be given
to key trials. Further research is warranted on methods
for efficiently finding larger trials.
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